Gary S. Jacob, Ph.D.

Gary S. Jacob, Ph.D. has served as Chairman and Director of ContraVir since May 2013. Dr. Jacob served as Chief Executive Officer of Callisto Pharmaceuticals, Inc. from May 2003 until January 2013 and a director from October 2004 until January 2013.  Dr. Jacob currently serves as a director of Trovagene, Inc., a public diagnostics company and a director and Chief Executive Officer of Synergy Pharmaceuticals Inc. since July 2008. Dr. Jacob also served as Chief Scientific Officer of Synergy from 1999 to 2003 and has over twenty-five years of experience in the pharmaceutical and biotechnology industries across multiple disciplines including research & development, operations and business development.  Prior to his involvement with Callisto and Synergy, Dr. Jacob was at Monsanto/G.D. Searle, where he served as Director of Glycobiology and Monsanto Science Fellow, specializing in the field of Glycobiology and drug discovery. From 1986 to 1990, Dr. Jacob managed the G.D. Searle Glycobiology Group located at Oxford University, England.

Dr. Jacob earned a B.S. in Chemistry from the University of Missouri, and holds a Ph.D. in Biochemistry from the University of Wisconsin-Madison.

Thomas H. Adams, Ph.D.

Thomas H. Adams, Ph.D. currently serves as Chairman of the Board for Trovagene Inc., a director of Synergy Pharmaceuticals, Inc. and a director and Chief Technology Officer of IRIS International, Inc. Dr. Adams served as Chairman and Chief Executive Officer of Leucadia Technologies, a privately held medical-device company, from 1998 to 2006, when Leucadia was acquired by IRIS.

Dr. Adams has significant public-company experience serving as a director of Invitrogen from 2000 to 2002 and as a director of Biosite Diagnostics, Inc. from 1989 to 1998. In 1989, he founded Genta, Inc., a publicly held biotechnology company in the field of antisense technology, and served as its Chief Executive Officer until 1997. He also founded Gen-Probe, Inc. in 1984 and served as its Chief Executive Officer and Chairman until its acquisition by Chugai Biopharmaceuticals, Inc. in 1989. Dr. Adams earned a Ph.D. in Biochemistry from the University of California, at Riverside.

John P. Brancaccio, C.P.A.

John P. Brancaccio, a retired C.P.A., has served as a Director of our company since May 2013. Since April 2004, Mr. Brancaccio has been the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies. From May 2002 until March 2004, Mr. Brancaccio was the Chief Financial Officer of Memory Pharmaceuticals Corp., a biotechnology company. From 2000 to 2002, Mr. Brancaccio was the Chief Financial Officer/Chief Operating Officer of Eline Group, an entertainment and media company. Mr. Brancaccio is currently a director of Tamir Biotechnology, Inc. and Trovagene, Inc.as well as a director of Synergy Pharmaceuticals Inc.

Timothy M. Block, Ph.D.

Timothy M. Block, Ph.D., has served as a Director of our company since October 2013. Dr. Block currently serves as Co-founder and President of the Hepatitis B Foundation (HBF) and its Baruch S. Blumberg Institute (formerly called the Institute for Hepatitis and Virus Research), the nation’s leading nonprofit organizations dedicated to improving the lives of those affected worldwide through research, education and patient advocacy. He also serves as President and CEO of the Pennsylvania (PA) Biotechnology Center, created by the HBF, which is home to more than 300 employees working in 36 small start-up life sciences and technology companies, and credited with more than $500 million beneficial impact on the region’s economy. Dr. Block is also Professor, Drexel University College of Medicine and Director of its Drexel Institute for Biotechnology and Virology Research.

Arnold Lippa, Ph.D.

Dr. Lippa has been Executive Chairman of the Board of Cortex Pharmaceuticals Inc., since March 2013, and was appointed Chief Scientific Officer in August 2015. Previously, he served as Chief Executive Officer and President. He is also Chairman of the Board of Xintria Pharmaceutical Corporation, which he co-founded in 2006.

Dr. Lippa is a Managing Member and founder of T Morgen Capital LLC, which is an investment and management company specializing in the creation and management of biomedical companies. Since 2005, T Morgen Capital has been a significant equity owner and a managing member of Aurora Capital LLC, a life science focused FINRA member firm, where Dr. Lippa represents T Morgen Capital as a Manager.

In 2004, Dr. Lippa co-founded and currently is representing T Morgen Capital, a Managing Member, as a Manager of Atypical BioCapital Management LLC and Atypical BioVentures Fund LLC, a life science fund management company and fund, respectively, both of which are affiliates of Aurora Capital.

Dr. Lippa was a founder of DOV Pharmaceutical, Inc., and served as Chairman of the Board and Chief Executive Officer from its inception in April 1995 until 2005. Prior to DOV, Dr. Lippa co-founded and co-managed a number of life sciences companies, including Praxis Pharmaceuticals, Inc., which he co-founded and took public in 1985, serving as President and Chief Operating Officer from 1984 until 1987.

Tamar D. Howson

Tamar D. Howson has served previously as Senior Vice President of Corporate and Business Development at both SmithKline Beecham (now GSK) and Bristol-Myers Squibb, as well as high-level positions at multiple other industry leaders. She has helped companies navigate external alliances, license negotiations, mergers and acquisitions, and venture capital investments. In 1999, she was awarded Healthcare Businesswomen’s Association’s “Woman of the Year” award.

In addition to ContraVir, Ms. Howson currently serves on the Board of Directors for the International Partnership for Microbicides, Organovo and Enzymotec. Ms. Howson earned a B.Sc. in Chemical Engineering from Technion in Haifa, Israel, an M.S. in Chemical Engineering from City College of New York, and an MBA in Finance, International Business and Marketing from Columbia University.

James Sapirstein, R.Ph., M.B.A.

James Sapirstein, Chief Executive Officer, brings over thirty years of pharmaceutical industry experience to Contravir. After beginning his career in 1984 as a sales representative with Eli Lilly, he accepted a position at Hoffmann-LaRoche in 1987, where he served for almost a decade as part of its sales and marketing teams. He held a number of positions at Hoffmann-LaRoche, including Product Director and International Operations Manager, and was actively involved with numerous product launches including several antivirals. In 1996, he became the Director of International Marketing of the Infectious Disease Division at Bristol Myers Squibb (BMS). Mr. Sapirstein directed the international HIV product marketing strategy at BMS and was an integral part of the international development and launch of a number of infectious disease products while at BMS.

More recently, Mr. Sapirstein has become known in the industry as a start-up and turnaround specialist, mainly for his work at Gilead Sciences, Inc. (GILD), Serono Laboratories, Inc., Tobira Therapeutics, Inc. and Alliqua Inc. (ALQA). Mr. Sapirstein served in the Global Marketing group at Gilead, beginning in 2000 where he led and developed the global marketing strategy for its flagship HIV drug, Viread. He played a key role in the development of the drug combination strategy that resulted in Gilead’s acquisition of Triangle’s nucleoside portfolio. That acquisition ultimately led to the launch of Truvada, Gilead’s multi-billion dollar combination HIV drug. In 2002, he accepted the position of Executive Vice President for Serono Laboratories where he led a team of over 100 professionals to rebuild a struggling HIV and pediatric growth hormone business. As CEO of privately held Tobira Therapeutics, a New Jersey based biopharmaceutical company focused on the development of novel HIV and infectious disease compounds, he was instrumental in helping to raise over $60 million in venture capital and research funding to enable Tobira to further its scientific development. As a result of those efforts, he was named one of New Jersey’s top 50 most influential people in healthcare in 2010 by NJBiz.com. Most recently, Mr. Sapirstein was CEO of Alliqua Therapeutics at Alliqua Inc., where he helped lead the transformation of transdermal wound care and drug delivery technology into a premier wound care organization. Mr. Sapirstein developed the growth strategies for the organization and was responsible for several key licensing opportunities which lead to an increased return on investment for all of the shareholders.